BPMC vs. ONC, TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, and SRPT
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.
Blueprint Medicines vs.
Blueprint Medicines (NASDAQ:BPMC) and Beigene (NASDAQ:ONC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.
Blueprint Medicines presently has a consensus price target of $123.83, suggesting a potential upside of 34.40%. Given Blueprint Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Blueprint Medicines is more favorable than Beigene.
Blueprint Medicines has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Beigene has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.
Blueprint Medicines has a net margin of -13.19% compared to Beigene's net margin of -25.94%. Beigene's return on equity of -25.12% beat Blueprint Medicines' return on equity.
48.6% of Beigene shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 7.4% of Beigene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Blueprint Medicines received 545 more outperform votes than Beigene when rated by MarketBeat users.
Blueprint Medicines has higher earnings, but lower revenue than Beigene. Blueprint Medicines is trading at a lower price-to-earnings ratio than Beigene, indicating that it is currently the more affordable of the two stocks.
In the previous week, Blueprint Medicines had 19 more articles in the media than Beigene. MarketBeat recorded 22 mentions for Blueprint Medicines and 3 mentions for Beigene. Beigene's average media sentiment score of 0.37 beat Blueprint Medicines' score of 0.26 indicating that Beigene is being referred to more favorably in the news media.
Summary
Blueprint Medicines beats Beigene on 10 of the 18 factors compared between the two stocks.
Get Blueprint Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
This page (NASDAQ:BPMC) was last updated on 2/21/2025 by MarketBeat.com Staff
Free BPMC Stock Alerts